Cartalax Dosage Protocol | PeptideDosages.com

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Cartalax (20 mg Vial) Dosage Protocol

Cartalax Dosage Chart

Cartalax is dosed at 2 mg–5 mg daily via subcutaneous injection in educational protocols. A 20 mg vial reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.

Example daily range: 2,000–5,000 mcg once daily (gradual titration).

Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Cartalax is a synthetic tripeptide bioregulator (Ala‑Glu‑Asp; sequence “AED”) developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology[1]. Preclinical studies indicate it may modulate fibroblast proliferation markers (Ki‑67), reduce pro‑apoptotic signaling (p53, caspase‑3), and support extracellular matrix homeostasis[2][3]. Note: Published human posology for subcutaneous Cartalax is limited; this framework extrapolates from available preclinical and observational data for educational purposes only.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Cartalax Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Route & Frequency: Subcutaneous, once daily. Evidence note: Specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance[2][8].

Weeks 1–2

2,000 mcg (2.0 mg)

30 units (0.30 mL)

Weeks 3–4

3,000 mcg (3.0 mg)

45 units (0.45 mL)

Weeks 5–8

4,000 mcg (4.0 mg)

60 units (0.60 mL)

Weeks 9–12

5,000 mcg (5.0 mg)

75 units (0.75 mL)

This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection volumes within typical SC tolerability parameters (≤~1.0 mL per site)[9][10].

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Insert needle through the stopper; let the diluent run slowly down the vial wall to avoid foaming.

Gently swirl or roll until fully dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration (average ~3.5 mg/day).

8 weeks ≈ 10 vials

12 weeks ≈ 15 vials

16 weeks ≈ 20 vials

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

8 weeks (10 vials): 30 mL → 3 × 10 mL bottles

12 weeks (15 vials): 45 mL → 5 × 10 mL bottles

16 weeks (20 vials): 60 mL → 6 × 10 mL bottles

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Concise summary of the once‑daily regimen.

Goal: Support connective‑tissue homeostasis and fibroblast function based on preclinical bioregulator research[2][3].

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).

Dose Range: 2,000–5,000 mcg daily with gradual titration.

Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.

Storage: Lyophilized: refrigerate or freeze; reconstituted: refrigerate; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

Start: 2,000 mcg daily; increase by ~1,000 mcg every 2 weeks as tolerated.

Target: 4,000–5,000 mcg daily by Weeks 5–12.

Frequency: Once per day (subcutaneous).

Cycle Length: 8–12 weeks; optional extension to 16 weeks.

Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term stability; protect from light and moisture[11].

Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.

Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.

Inject slowly; wait a few seconds before withdrawing the needle.

Document daily dose and site rotation to maintain consistency.

Evidence caveat: Published human clinical trial data for subcutaneous Cartalax is limited; this protocol extrapolates from preclinical studies and standard peptide handling practices.

How This Works

Cartalax (Ala‑Glu‑Asp) is classified among the Khavinson bioregulatory peptides—ultrashort peptides that may interact with DNA and modulate gene expression at nanomolar concentrations[1][4]. The peptide sequence corresponds to a motif found in the alpha‑1 chain of type XI collagen, a structural protein important for cartilage integrity[5]. In preclinical fibroblast and chondrocyte culture models, Cartalax has been reported to upregulate Ki‑67 (a proliferation marker), increase SIRT‑1/SIRT‑6 expression, reduce p53 and caspase‑3 activity (pro‑apoptotic signals), and inhibit MMP‑9 synthesis (an enzyme linked to extracellular matrix degradation)[2][3][6].

Potential Benefits & Side Effects

Observations from preclinical literature.

May support fibroblast proliferation and reduce markers of cellular senescence in aged cell cultures[2][3].

Preclinical data suggest modulation of extracellular matrix homeostasis via MMP‑9 inhibition and collagen‑related gene expression[6].

General tolerability: Khavinson bioregulator peptides have been described as well tolerated in observational settings; occasional mild injection‑site reactions (redness, itch) may occur with subcutaneous administration[1].

Limitations: No large‑scale human RCTs; most data derive from in vitro or rodent models.

Lifestyle Factors

Complementary strategies for best outcomes.

Support joint and connective‑tissue health with adequate protein, vitamin C, and collagen precursors.

Combine low‑impact exercise and mobility work to reinforce musculoskeletal adaptations.

Prioritize sleep and stress management to support tissue repair and recovery.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[8][12].

Clean the vial stopper and skin with alcohol; allow to dry.

Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8].

Do not aspirate for subcutaneous injections; inject slowly and steadily[8].

Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[12].

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References

Neuroendocrinology Letters (2002) — Khavinson VK. Peptides and Ageing. Overview of bioregulatory peptide development and geroprotective mechanisms. View Source

Bulletin of Experimental Biology and Medicine (2016) — Lin’kova NS et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. AED peptide effects on Ki‑67, CD98hc, caspase‑3, and MMP‑9. View Source

Bulletin of Experimental Biology and Medicine (2014) — Khavinson VK et al. Peptides regulate the expression of signaling molecules in kidney cell cultures during in vitro aging (p53, p16, SIRT‑6). View Source

Molecular Biology Reports (2020) — Ashapkin V, Khavinson V et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. View Source

International Journal of Molecular Sciences (2023) — Linkova N, Khavinson V et al. Peptide Regulation of Chondrogenic Stem Cell Differentiation. View Source

Advances in Gerontology (2020) — Khavinson VK, Linkova NS et al. Short peptides: regulation of skin function during aging (collagen, SIRT‑1/‑6, MMP regulation). View Source

CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration). View Source

Advances in Therapy (PubMed) — Subcutaneous injection factors and tolerability; practical volume considerations. View Source

StatPearls (NCBI Bookshelf) — Medication routes of administration; cautions for large single‑site SC volumes. View Source

Bachem — Handling and Storage Guidelines for Peptides (lyophilized and reconstituted stability). View Source

NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration). View Source

Additional Research and Background

These sources provide related context and are not presented as support for a specific statement above.

PubChem — Compound summary for Cartalax (AED peptide; CID 87815447): molecular formula C₁₂H₁₉N₃O₈, MW 333.29. View Source

Related research, protocols, and guides

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.

Research overview

Cartalax Peptide: Benefits, Uses, Side Effects, Dosage, and Research

Practical guides

Single Peptide Dosages

Peptide Dosage & Reconstitution Calculator

How to Reconstitute Peptides

Syringe & Measurement Guide

Peptide Storage Guide

Peptide Dosage Chart

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Key takeaways

Cartalax is dosed at 200–400 mcg per day in research models, administered subcutaneously during the early active phase for maximum receptor engagement.
Reconstitution must use bacteriostatic water at a 1:1 ratio (1 mL per 1 mg), added slowly down the vial wall without agitation to prevent oxidative denaturation.
Reconstituted solutions remain stable for 28 days when refrigerated at 2–8°C. Any temperature excursion above 8°C causes irreversible potency loss.
Standard research cycles run 10–20 days with 3–6 month rest intervals; continuous dosing causes receptor downregulation that reduces observed effects by 30–40%.
Light exposure and mechanical agitation are the two most common unrecognised protocol errors that silently degrade peptide bioactivity without changing visual appearance.

realpeptides.co

Related questions

01IGF-1 DES — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 1 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 1 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. IGF-1 DES is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

02Cortexin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Cortexin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

03Humanin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Humanin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

04Pemvidutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Pemvidutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

05AHK-Cu — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. AHK-Cu is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

Research context

Read sources and limitations before applying a claim.

Important Research Note

Published human SNAP-8 research uses complete topical products and localized dissolving patches. Interpret each result with its vehicle, co-ingredients, delivery system, application schedule, and measurement method.

Source: peptidedosages.com ↗

Where the Human Evidence Stands — and Why It Does Not Reach Lipogenesis

AOD-9604’s clinical record lives almost entirely in obesity, and understanding it is the fairest way to gauge whether any of the preclinical antilipogenic promise translated to people. The short version: it was tested seriously, in humans, at scale, and it did not deliver on its primary endpoint — and none of the human work measured lipogenesis at all. Across development, AOD-9604 was studied in roughly six human clinical trials enrolling more than 900 participants in total, a tally that derives from the sponsor’s development-program summary rather than a single publication.10 The centerpiece early study, a 12-week Phase 2 evaluation in obese adults (METAOD005) using once-daily oral dosing across several dose arms, was encouraging: the 1 mg arm reportedly lost more weight than placebo, and the results generated optimistic press.10 But the pivotal, longer, more rigorously controlled 24-week study (METAOD006) — a randomized, double-blind, placebo-controlled, multicenter trial that is the single published RCT on the compound — found that the weight-loss difference between AOD-9604 and placebo did not reach statistical significance at the primary endpoint, especially against a background of intensive diet and exercise.10 Development as an obesity drug was terminated in 2007. Two points matter for the antilipogenic question. First, every human study used weight and body-composition endpoints, plus safety and pharmacokinetic measures. None used the tools that actually quantify de novo lipogenesis in people — stable-isotope tracers (for example, deuterated water incorporation into palmitate), adipose or hepatic lipogenic-gene expression, or measured lipogenic flux. So even the human trials that exist are silent on whether AOD-9604 reduces fat synthesis; they measured the downstream outcome (weight), not the mechanism (lipogenesis), and the downstream outcome was not robustly positive. Second, the reassuring endocrine profile held up: the compound was reported not to raise IGF-1 and not to impair glucose tolerance, consistent with the “GH activity modulation” design.1 Trials ~6 studies, >900 participants total10 Pivotal design 24-week randomized, double-blind, placebo-controlled, multicenter (METAOD006); oral10 Primary endpoint Weight difference vs placebo did NOT reach statistical significance10 Lipogenesis measured? No — no DNL tracer, lipogenic-gene, or flux endpoints in any human study Endocrine profile No reported IGF-1 rise; no impaired glucose tolerance1 Outcome Obesity development halted in 200710 The honest reading is stark: the compound’s best-evidenced outcome (fat loss in obesity) was itself not robustly demonstrated in humans, and its proposed mechanism (reduced lipogenesis) was never measured in humans at all. Extrapolating from “inhibited ACC in rat fat pads” to “reduces lipogenesis in people” is a leap across species, tissues, and measurement methods, with no human data on the far side. For a measured look at how the clinical results are often characterized, see the site’s summary of what clinical trials indicate about the fat-burning potential of AOD-9604.

Source: dosagepeptide.com ↗

Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

HMG (75IU Vial) Dosage Protocol

Menotropins (FSH + LH) — FDA-approved for female fertility; the male-fertility protocol here is off-label.

Source: dosagepeptide.com ↗

Storage reference

Storage Instructions

Proper storage preserves compound stability. Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months[4]. Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks. Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues. Do not refreeze reconstituted solution.

Source: peptidedosages.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Cartalax (20 mg Vial) Dosage Protocol

Cartalax Dosage Chart

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Reconstitution Steps

Supplies Needed

Protocol Overview

Dosing Protocol

Storage Instructions

Important Notes

How This Works

Potential Benefits & Side Effects

Lifestyle Factors

Injection Technique

Important Note

References

Additional Research and Background

Related questions

Important Research Note

Where the Human Evidence Stands — and Why It Does Not Reach Lipogenesis

HMG (75IU Vial) Dosage Protocol

Storage Instructions

Peptide Therapy Guide Editorial Team

Vilon Dosage Protocol | PeptideDosages.com

Vesugen Dosage Protocol | PeptideDosages.com

Testagen Dosage Protocol | PeptideDosages.com

SS-31 30mg Dosage Protocol | PeptideDosages.com